March 6, 2018 / 12:41 PM / 5 months ago

BRIEF-Clearside Biomedical Provides Update On Two Phase 3 Clinical Trials Of CLS-TA In Retinal Vein Occlusion

March 6 (Reuters) - Clearside Biomedical Inc:

* CLEARSIDE BIOMEDICAL PROVIDES UPDATE ON TWO PHASE 3 CLINICAL TRIALS OF CLS-TA IN RETINAL VEIN OCCLUSION

* CLEARSIDE BIOMEDICAL INC - ‍NOW EXPECTS TO REPORT PRELIMINARY DATA FROM SAPPHIRE TRIAL IN Q4 OF 2018 INSTEAD OF Q1 OF 2019​

* CLEARSIDE BIOMEDICAL - ‍IF PRIMARY ENDPOINTS MET IN BOTH TOPAZ AND SAPPHIRE TRIALS, CO EXPECTS TO SEEK AGNOSTIC LABEL IN U.S. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below